SCHEMBL22334247

SCHEMBL22334247

Cc1cc(-n2ncnc2C)c2cccc(OCc3c(Cl)cc(F)cc3[C@H](C)NC(=O)CC(F)F)c2n1

nearest known ligand 0.41

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BDKRB2 P30411 19/20 0.41
GPR139 Q6DWJ6 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24426968 0.94 BDKRB2 (0.41) BDKRB2CYP3A4
SCHEMBL21030155 0.92 BDKRB2 (0.40) BDKRB2GPR139CYP3A4
SCHEMBL22320048 0.92 BDKRB2 (0.40) BDKRB2GPR139CYP3A4
SCHEMBL26901990 0.91 BDKRB2 (0.42) BDKRB2CYP3A4
SCHEMBL21030180 0.91 BDKRB2 (0.42) BDKRB2CYP3A4
SCHEMBL26901989 0.91 BDKRB2 (0.42) BDKRB2CYP3A4
SCHEMBL21030529 0.91 BDKRB2 (0.42) BDKRB2CYP3A4
SCHEMBL21030185 0.91 BDKRB2 (0.40) BDKRB2GPR139CYP3A4
SCHEMBL21030802 0.90 BDKRB2 (0.42) BDKRB2CYP3A4
SCHEMBL21031782 0.90 BDKRB2 (0.39) BDKRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820756-B2 Bradykinin B2 receptor antagonists Pharvaris Netherlands B.V. (NL) 2023-11-21 US disclosed
US-11820756-B2 Bradykinin B2 receptor antagonists Pharvaris Netherlands B.V. (NL) 2023-11-21 US disclosed
US-20220135543-A1 NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS Pharvaris Netherlands B.V. (NL) 2022-05-05 US disclosed
US-20210017158-A1 NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS ANALYTICON DISCOVERY GMBH (DE) 2021-01-21 US disclosed
US-10836748-B2 Bradykinin B2 receptor antagonists Pharvaris Netherlands B.V. (NL) 2020-11-17 US disclosed
US-20200255405-A1 NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS ANALYTICON DISCOVERY GMBH (DE) 2020-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210017158-A1 NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS BDKRB2, BDKRB1, VIPR2 BDKRB2 1/4885GPR139 193/4885CYP3A4 2143/4885
US-20220135543-A1 NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS BDKRB2, BDKRB1, VIPR2 BDKRB2 1/4885GPR139 193/4885CYP3A4 2143/4885
US-10836748-B2 Bradykinin B2 receptor antagonists BDKRB2, BDKRB1, VIPR2 BDKRB2 1/4885GPR139 324/4885CYP3A4 1840/4885
US-11820756-B2 Bradykinin B2 receptor antagonists BDKRB2, BDKRB1, VIPR2 BDKRB2 1/4885GPR139 324/4885CYP3A4 1840/4885
US-20200255405-A1 NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS BDKRB2, BDKRB1, VIPR2 BDKRB2 1/4885GPR139 193/4885CYP3A4 2143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.